Filing Flows › 60 Degrees Pharmaceuticals (SXTP) › Q3 2025
60 Degrees Pharmaceuticals (SXTP) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 13, 2025
60 Degrees Pharmaceuticals (SXTP) reported revenue of $438K for the third quarter 2025 (Q3 2025), +223% from a year earlier and +334% from the quarter before. Operating margin was -531.4%, net loss $2.3M (529.5% of revenue).
60 Degrees Pharmaceuticals, Q3 2025: revenue $438K (+223% year over year), operating margin -531.4%, net loss $2.3M, operating cash flow −$2.1M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $438K | +334% | +223% |
| Operating profit | −$2.3M | — | — |
| Net earnings | −$2.3M | — | — |
| Operating cash flow | −$2.1M | — | — |
What changed
Revenue was $438K in Q3 2025, up 223% year over year and up 334% from the previous quarter.
Operating costs exceeded revenue by $2.3M, an operating margin of -531.4%. The quarter ended with a net loss of $2.3M, wider than the previous quarter's $1.7M loss. Minority interests bore $1K of it: to shareholders the quarter was a loss of $2.3M.
Operating cash flow was −$2.1M. Non-cash charges added back $23K of depreciation and amortization and $79K of share-based compensation. Working capital and other items added $106K. Capital expenditures of $10K exceeded it, leaving free cash flow of −$2.1M.
Questions
What was 60 Degrees Pharmaceuticals' revenue in the third quarter 2025?
60 Degrees Pharmaceuticals (SXTP) reported revenue of $438K for the third quarter 2025 (Q3 2025), +223% from a year earlier and +334% from the quarter before.
Was 60 Degrees Pharmaceuticals profitable in the third quarter 2025?
Operating loss was $2.3M (-531.4% of revenue) and net loss $2.3M.